Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 15Triple Negative Breast Neoplasms 12Lung Neoplasms 12Neoplasm Metastasis 11Ovarian Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Fallopian Tube Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Adenocarcinoma Of Esophagus 4Mouth Neoplasms 3Laryngeal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Inflammatory Breast Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Esophageal Squamous Cell Carcinoma 2Brenner Tumor 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Taxes × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡